Effect of treatment with direct acting antivirals on body mass index and hepatic steatosis in chronic hepatitis C

Direct Acting Agents (DAAs) have high cure rate but still lack the knowledge of their effect on hepatic steatosis in chronic hepatitis C (CHC). Controlled Attenuation Parameter (CAP), evaluated with transient elastography, could help in assessment of steatosis grades. We aim to evaluate the effect o...

Full description

Saved in:
Bibliographic Details
Published in:Journal of medical virology 2018-06, Vol.90 (6), p.1099-1105
Main Authors: Shousha, Hend I., Abdelaziz, Rasha A., Azab, Sherief M., Khairy, Marwa, Afifi, Shahira A., Mehrez, Mai I., Eshra, Mohamed A., Abdelrahim, Ayman Y.
Format: Article
Language:English
Subjects:
Antiviral agents
Antiviral drugs
Body mass
Body mass index
Body size
chronic hepatitis C
controlled attenuation parameter (CAP)
direct acting antivirals
Fatty liver
Females
hepatic steatosis
Hepatitis
Hepatitis C
Liver
Patients
Steatosis
Stiffness
Virology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Direct Acting Agents (DAAs) have high cure rate but still lack the knowledge of their effect on hepatic steatosis in chronic hepatitis C (CHC). Controlled Attenuation Parameter (CAP), evaluated with transient elastography, could help in assessment of steatosis grades. We aim to evaluate the effect of DAAs on BMI and steatosis in CHC using CAP. This cohort study included 155 CHC Egyptian patients divided into three groups according to the DAAs regimens. All patients were subjected to pre‐treatment and 3‐months post‐treatment evaluation including BMI, laboratory workup and liver stiffness measurement with simultaneous CAP determination using the (FibroScan®) M probe. Patients mean age was 45.78 ± 11.6 years, 60.6% were females, mean BMI 26.63 ± 2.75 and 18.1% were cirrhotic. Baseline assessment revealed no steatosis in 43.9%, 32.9% had mild‐moderate steatosis and 23.2% had severe steatosis. The overall sustained virological response 12 was 93.6%. Follow‐up revealed stationary steatosis in 56.7% of patients and regression in 21.3%. Mean pre‐treatment CAP were significantly lower in responders 244.9 ± 62.4 dB/m versus non‐responders; 300 ±28.4 dB/m (P = 0.04). ROC curve delineated 273 dB/m as best cutoff for detection of responders with an AUC of 0.801, sensitivity 68.2%, and specificity 100%. BMI significantly increased after treatment (P = 0.004) particularly in patients with worsened steatosis (P = 0.001). Steatosis significantly correlated with BMI (r = 0.3, P value = 
ISSN:0146-6615
1096-9071
DOI:10.1002/jmv.25062